PO.ET06.03 · 实验与分子治疗

DACH1基因肿瘤抑制因子的缺失增加前列腺癌中的复制叉应激、上皮间质转化及对WEE1激酶抑制剂的敏感性

Deletion of the DACH1 gene tumor suppressor increases replication fork stress, epithelial mesenchymal transition and sensitivity to WEE1 kinase inhibitors in prostate cancer

海报缩略图:DACH1基因肿瘤抑制因子的缺失增加前列腺癌中的复制叉应激、上皮间质转化及对WEE1激酶抑制剂的敏感性
编号 1751 展板 17 时间 4/20 09:00–12:00 区域 Section 14 主讲 Xuanmao Jiao, BS;PhD
分会场 DNA Damage and Repair 2
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Danni Li1, Arijit Ghosh2, Zhiping Li1, Kenneth Iczkowski3, Hidetoshi Mori4, Samiha Nasser5, Csaba Kerepesi5, Andras Benczur5, Hallgeir Rui6, Ritika Harish1, Li Lan7, Xuanmao Jiao1, Fred Saad8, Janne Purhonen7, Anthony W. Ashton9, Richard G. Pestell1

1Baruch S. Blumberg Institute, Wynnewood, PA,2Duke University School of Medicine, Durham, NC,3UC Davis Health, Sacramento, CA,4UC Davis, Davis, CA,5Hungarian Research Network, Budapest, Hungary,6Thomas Jefferson University, Philadelphia, PA,7Karolinska Institutet, Stockholm, Sweden,8Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada,9Lankenau Institute for Medical Research, Wynnewood, PA

摘要 Abstract

中文摘要
• 引言:具有DNA损伤修复通路异常的转移性前列腺癌患者生存期差。细胞命运决定因子DACH1在约5-12%的前列腺癌(PCa)患者中发生缺失(浅缺失或深缺失),但在高达65%的转移性PCa中发生缺失。WEE1激酶是人前列腺癌激酶组中上调最显著的激酶之一,与前列腺癌(mCRPC)的转移进展相关。我们基于DACH1表达谱确定了PCa对WEE1激酶抑制剂(WEE1Ki)差异敏感性的潜力。 • 方法:对患者基因表达、肿瘤组织学、源自前列腺上皮细胞特异性DACH1缺失前列腺肿瘤小鼠的类器官、DNA复制叉实验、组织培养进行分析。 • 发现:DACH1缺陷(Dach1-/-)细胞对WEE1Ki的杀伤作用增强,而重新引入DACH1a可逆转这一效应。在成纤维细胞、前列腺癌细胞系以及源自人前列腺癌细胞系或Dach1缺失肿瘤小鼠前列腺上皮的类器官中,均显示出对WEE1Ki敏感性的增加。DACH1缺失在WEE1Ki存在的情况下显著增强了非复制性S期。Dach1-/-细胞表现出复制叉应激增加,而重新引入DACH1a异构体可将其逆转。DACH1上皮细胞缺失肿瘤小鼠及由此衍生的前列腺类器官与上皮间质转化(EMT)的诱导相关,同时AKT Ser473P、ATR Thr1989p和CHK1 Ser345P相应增加。对WEE1Ki敏感性的增加与SETD2或NSD1/KMT3B表达降低以及核糖核苷酸还原酶亚基RRM2降低相关,从而诱导dNTP匮乏。DACH1表达与SETD2、NSD1和RRM2高度相关。与DACH1 DNA结合模板相关的基因本体术语包括核苷代谢过程。与其他几种肿瘤抑制基因(RB、FOXO3)类似,DACH1抑制dNTP的产生。dNTP的产生还需要由NME基因编码的NDPK(核苷二磷酸激酶)。与dNTP产生受抑制相一致,DACH1a在前列腺癌PC3细胞中的表达降低了NME1和NME7(NDPKA表达),且在人前列腺癌中DACH1与NME1呈强烈负相关(N=491,P 9.9e-24)。 • 结论:由于DACH1缺失的PCa亚类具有特定的治疗敏感性,且该敏感性依赖于DACH1a异构体,因此在患者样本中检测DACH1a可能是有必要的。
查看英文原文 English abstract
• Introduction: Patients with metastatic prostate cancer have poor survival with DNA damage repair pathway abnormalities. The cell fate determination factor DACH1 is deleted (shallow or deep deletion) in ~5-12% of PCa patients, but up to 65% of metastatic PCa. WEE1 kinase is one of the most upregulated kinases in the human prostate cancer kinome associated with metastatic progression in prostate cancer (mCRPC). We determined the potential for differential sensitivity of PCa to Wee1 Kinase inhibitors (WEE1Ki) based on DACH1 expression profiles. • Methods: Analysis of patient gene expression, tumor histology, organoids derived from prostate epithelial cell-specific DACH1 deletion prostate onco-mice, DNA replication fork assays, tissue culture. • Findings: DACH1 deficient ( Dach1 -/- ) cells showed enhanced cell killing by WEE1Ki, that was reversed by reintroduction of DACH1a. Increased sensitivity to WEE1Ki was shown in fibroblasts, prostate cancer cell lines and in organoids derived from human prostate cancer cell lines or the prostate epithelium of Dach1 deletion onco-mice. DACH1 deletion dramatically enhanced non replicating S phase in the presence of WEE1Ki. Dach1 - /- cells showed increased replication fork stress, that was reversed by reintroduction of the DACH1a isoform. DACH1 epithelial cell deletion onco-mice, and the prostate organoids derived therefrom, was associated with the induction of epithelial mesenchymal transition (EMT) with a corresponding increase in AKT Ser473P , ATR Thr1989p and CHK1 Ser345P . Increased sensitivity to WEE1Ki is associated with reduced SETD2 or NSD1/KMT3B expression, and reduced RRM2, a ribonucleotide reductase subunit, thereby inducing dNTP starvation. DACH1 expression was highly correlated with SETD2, NSD1 and RRM2. Gene ontology terms associated with DACH1 DNA binding templates included nucleoside metabolic processes. Like several other tumor suppressor genes (RB, FOXO3), DACH1 restrained dNTP production. dNTP production also requires NDPK (Nucleoside Diphosphate Kinase) encoded by NME genes. Consistent with the inhibition of dNTP production, DACH1a expression in prostate cancer PC3 cells reduced NME1 and NME7 (NDPKA expression), and DACH1 was strongly inversely correlated with NME1 in human prostate cancer (N=491. P 9.9e-24). • Conclusions: As DACH1 deletion PCa subclass conveys specific therapeutic sensitivities, that is dependent upon the DACH1a isoform, testing for DACH1a in patient samples may be warranted.
利益披露 Disclosure
D. Li, Stromagenesis LLC ). ). Cytodyn Inc ). ). Ecogenome LLC ). ). A. Ghosh, None. Z. Li, Stromagenesis LLC ). Ecogenome LLC ). Lightseed LLC ). Cytodyn Inc ). K. Iczkowski, None.. H. Mori, None.. S. Nasser, None.. C. Kerepesi, None.. A. Benczur, None.. H. Rui, None. R. Harish, Stromagenesis LLC ). Cytodyn Inc ). Lghtseed LLC ). Ecogenome LLC ). L. Lan, None. X. Jiao, Stromagenesis LLC ). Lightseed LLC ). Ecogenome LLC ). Cytodyn Inc ). F. Saad, None.. J. Purhonen, None.. A. W. Ashton, None. R. G. Pestell, CytoDyn Inc Stock, ), Travel, Consultant, Warrants. HUN-REN National Advisory Board (Hungary) Consultant, Payment or honoraria for lectures. StromaGenesis LLC. Stock, Travel, Patent, CEO and owner. EcoGenome LLC Stock, Travel, Patent, CEO and owner. LightSeed LLC Stock, Travel, Patent, CEO and owner. Shenandoah Pharmaceuticals LLC Stock, Travel, Patent, CEO and owner. ioROC Therapeutics LLC Stock, Travel, Patent, CEO and owner. National Cancer Institute NCI Cancer Center Reviewer – Subcommittee A.

← 返回 AACR 2026 检索